FibroBiologics (FBLG) Current Deferred Revenue (2024)
FibroBiologics' (FBLG) quarterly Current Deferred Revenue came in at $241000.0 in Q3 2024, down 83.93% quarter-over-quarter from $1.5 million in Q2 2024.
Powered by 
Analysis
FibroBiologics (FBLG) Current Deferred Revenue (2024) Analysis & Trends
FibroBiologics (FBLG) has reported Current Deferred Revenue for 1 consecutive years, with $241000.0 the latest figure, recorded in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | FibroBiologics | 10.66 Mn | 10.66 Mn | - |